辉瑞:新冠病毒疫苗最早10月进行接受监管审查
辉瑞(Pfizer)(PFE.US)表示,与BioNTech共同开发的新冠病毒疫苗,最早将於10月进行监管审查。
辉瑞周四已公布更多疫苗的研究数据,目前疫苗正在美国及德国进行第2及第3期测试,在接受测试的年轻及老年人当中,低於20%出现轻微至中度的发烧。。
辉瑞疫苗研究与开发负责人Kathrin Jansen表示,疫苗在美国首阶段测试能在人体身上产生抗体,短期内会公布在德国测试中发现的T细胞免疫反应数据。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.